THE Pfizer signed a $ 5.29 billion deal with the government of USA for the delivery of its ten million doses antiviral drug of against him coronavirus starting this year, according to today’s announcement of the pharmaceutical industry.
Oral medicine can be a promising new weapon in the fight against pandemic, as it can be administered from early for home treatment helping to prevent hospitalizations and deaths from COVID-19, broadcasts by ΑΠΕ ΜΠΕ.
It is recalled that Pfizer submitted an application to the FDA for licensing of this drug, Paxlovid, the day before yesterday, Tuesday, according to a relevant announcement.
He stated, however, that he expects to prepare 180,000 doses by the end of next month and at least 50 million doses by the end of 2022.
“This promising treatment could help speed the way out of this pandemic by offering another life-saving tool for people with COVID-19,” he said. Javier Besera, US Secretary of Health and Human Services.
Findings of the pill study
The company announced earlier this month that the drug is reducing by 89% the likelihood of hospitalization or death of adults at risk of serious illness.
In fact. The test results show that Pfizer is the drug more effective from Merck pill, molnupiravir, which last month showed halving the risk of death or hospitalization for COVID-19 patients at high risk of serious illness.
However, the US government has signed a contract $ 2.2 billion and for doses of Merck drug.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
.jpg "All the sport that can be seen in this summer: here is the programming of Sky from engines to tennis")
